

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

|                  |                |
|------------------|----------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
|------------------|----------------|

|                       |                   |
|-----------------------|-------------------|
| NATURE OF CONVEYANCE: | SECURITY INTEREST |
|-----------------------|-------------------|

|                                |          |                |                          |
|--------------------------------|----------|----------------|--------------------------|
| CONVEYING PARTY DATA           |          |                |                          |
| Name                           | Formerly | Execution Date | Entity Type              |
| Hawthorn Pharmaceuticals, Inc. |          | 11/26/2003     | CORPORATION: MISSISSIPPI |

|                      |                                       |
|----------------------|---------------------------------------|
| RECEIVING PARTY DATA |                                       |
| Name:                | Madison Capital Funding LLC, as Agent |
| Street Address:      | 30 West Monroe Street                 |
| Internal Address:    | Suite 3700                            |
| City:                | Chicago                               |
| State/Country:       | ILLINOIS                              |
| Postal Code:         | 60606                                 |
| Entity Type:         | Limited Liability Company: DELAWARE   |

| PROPERTY NUMBERS Total: 3 |          |           |
|---------------------------|----------|-----------|
| Property Type             | Number   | Word Mark |
| Serial Number:            | 76525101 | ICAR      |
| Serial Number:            | 76525102 | XIRATUSS  |
| Serial Number:            | 76525103 | DYTAN     |

|  |                                  |
|--|----------------------------------|
| CORRESPONDENCE DATA  |                                  |
| Fax Number:  | (312)863-7812                    |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> |                                  |
| Phone:   | 312-863-7190                     |
| Email:   | nathaniel.panek@goldbergkohn.com |
| Correspondent Name:  | Nathaniel Panek                  |
| Address Line 1:  | 55 E. Monroe Street              |
| Address Line 2:  | Ste. 3700                        |
| Address Line 4:  | Chicago, ILLINOIS 60603          |

|                         |          |
|-------------------------|----------|
| ATTORNEY DOCKET NUMBER: | 4975.041 |
|-------------------------|----------|

|                    |                 |
|--------------------|-----------------|
| NAME OF SUBMITTER: | Nathaniel Panek |
|--------------------|-----------------|

OP \$90.00 76525101

Total Attachments: 5

source=Hawthorn#page1.tif

source=Hawthorn#page2.tif

source=Hawthorn#page3.tif

source=Hawthorn#page4.tif

source=Hawthorn#page5.tif

## TRADEMARK SECURITY AGREEMENT

TRADEMARK SECURITY AGREEMENT, dated as of November 26, 2003, by HAWTHORN PHARMACEUTICALS, INC., a Mississippi corporation ("Grantor"), in favor of MADISON CAPITAL FUNDING LLC, in its capacity as agent ("Agent") for Lenders (as herein after defined).

### WITNESSETH:

WHEREAS, pursuant to that certain Credit Agreement dated as of even date herewith by and among Grantor, Cypress Pharmaceuticals, Inc. ("Cypress"), Agent and the lenders ("Lenders") from time to time party thereto (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Credit Agreement"), Lenders have agreed to make the Loans and to issue Letters of Credit for the benefit of Grantor;

WHEREAS, Agent and Lenders are willing to make the Loans and to issue Letters of Credit as provided for in the Credit Agreement, but only upon the condition, among others, that Grantor, together with Cypress, shall have executed and delivered to Agent, for itself and the ratable benefit of Lenders, that certain Guaranty and Collateral Agreement dated as of even date herewith (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Collateral Agreement"); and

WHEREAS, pursuant to the Collateral Agreement, Grantor is required to execute and deliver to Agent, for itself and the ratable benefit of Lenders, this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees as follows:

1. DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Collateral Agreement.

2. GRANT OF SECURITY INTEREST IN TRADEMARK COLLATERAL. Grantor hereby grants to Agent, on behalf of itself and Lenders, a continuing first priority security interest in all of Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Trademark Collateral"):

(a) all of its Trademarks and Trademark Licenses to which it is a party including, but not limited to, those Trademark Licenses which are material to the conduct of Grantor's business and the United States federally registered Trademarks referred to on Schedule I hereto;

- (b) all reissues, continuations or extensions of the foregoing;
- (c) all goodwill of the business connected with the use of, and symbolized by, each Trademark and each Trademark License; and
- (d) all products and proceeds of the foregoing, including, without limitation, any claim by Grantor against third parties for past, present or future (i) infringement or dilution of any Trademark or Trademark licensed under any Trademark License or (ii) injury to the goodwill associated with any Trademark or any Trademark licensed under any Trademark License.

3. COLLATERAL AGREEMENT. The security interests granted pursuant to this Trademark Security Agreement are granted in conjunction with the security interests granted to Agent, on behalf of itself and Lenders, pursuant to the Collateral Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

[signature page follows]

IN WITNESS WHEREOF, Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**HAWTHORN PHARMACEUTICALS, INC.**

By *Max Draughn*  
Name MAX DRAUGHN  
Title President

ACCEPTED AND ACKNOWLEDGED BY:

**MADISON CAPITAL FUNDING LLC, as Agent**

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

**ACKNOWLEDGMENT OF GRANTOR**

STATE OF )  
                  ) SS  
COUNTY OF )

On this 26 day of November, 2003 before me personally appeared Max Draughn, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of Cypress Pharmaceuticals, Inc., who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.

{seal}

*Leigh Stringer*  
Notary Public

Notary Public State of Mississippi At Large  
My Commission Expires: December 9, 2005  
Bonded Thru Helden, Brooks & Garland, Inc.



**SCHEDULE I**  
**to**  
**TRADEMARK SECURITY AGREEMENT**

**TRADEMARK REGISTRATIONS**

None

**TRADEMARK APPLICATIONS**

| <b>MARK</b> | <b>STATUS</b>       | <b>SERIAL NO.</b> | <b>FIRST USE DATE</b> |
|-------------|---------------------|-------------------|-----------------------|
| Icar        | Pending-Initialized | 76-525101         | 11/98                 |
| Xiratuss    | Pending-Initialized | 76-525102         | 11/01                 |
| Dytan       | Pending-Initialized | 76-525103         | 11/01                 |

**TRADEMARK LICENSES**

None